[Skip to Content]
[Skip to Content Landing]
Editorial
May 19, 2015

Defining Amyloid Pathology in Persons With and Without Dementia Syndromes: Making the Right Diagnosis

Author Affiliations
  • 1University of Texas Southwestern Medical Center at Dallas, Department of Neurology and the Alzheimer’s Disease Center, Dallas
  • 2Editor, JAMA Neurology
JAMA. 2015;313(19):1913-1914. doi:10.1001/jama.2015.5361

In this issue of JAMA, 2 articles from the Netherlands report findings from meta-analyses that assess the prevalence of amyloid pathology as determined by biomarkers in persons with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI)1 and estimate the prevalence of amyloid positivity on amyloid-β positron emission tomography (PET) in a wide variety of dementia syndromes.2 These reports are the largest and most detailed to date and are critical assessments that help define the role of amyloid in the causation of cognitive impairment and dementia.

×